Summary of Study ST002553

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001645. The data can be accessed directly via it's Project DOI: 10.21228/M82M7C This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST002553
Study Title	Exploring the Impact of Oral Arabic Gum Consumption on Sphingolipid Metabolism and human metabolites in Chronic Kidney Disease: A Mass Spectrometry Analysis
Study Type	LC/MS/MS
Study Summary	Globally, the incidence of chronic kidney disease is increasing, raising serious concerns about its impact on public health. It also poses significant difficulty in finding novel early diagnostics, understanding biochemical pathways, monitoring patients, and prognosis. Any metabolite found in a biofluid, or tissue may act as a driver, signal, or both in the emergence or spread of the disease. As a result, metabolomics is a very useful strategy in this therapeutic setting. Broad metabolite coverage is essential since it strives to offer a representative image of a biological system. An untargeted metabolomics-based method was used in this cross-sectional study to identify metabolomic changes and their relationship to pathways in the Arabic gum patient group and control participants. Plasma samples were collected from 88 participants who met the inclusion criteria, of whom 43 control patients were treated with a placebo and 45 intervention patients were treated with Arabic gum. Highly sensitive ultra-high-performance liquid chromatography with electrospray ionization and quadrupole time-of-flight mass spectrometry was used to analyze the plasma samples (UHPLC-ESI-QTOF-MS). We investigated the effect of Arabic gum on individual metabolites using a two-tailed independent student t-test. The results showed that 31 out of 92 identified metabolites were found to be statistically significant (p < 0.05). L-Leucine and 5'-Methylthioadenosine were the significantly increased metabolites in the Arabic gum group. Conversely, triethylamine, D-limonene, 4-methylphenylacetic acid, and sphingosine levels were significantly lower in the Arabic gum group compared to the control. Arabic gum primarily affected multiple metabolic pathways, including glycine and serine, arginine and proline, valine, leucine, and isoleucine degradation, phenylalanine and tyrosine, urea cycle, and sphingolipid. The results from this study provide insights into the potential diagnostic significance of different metabolites in chronic kidney disease and their impact on specific metabolic pathways. However, further research involving larger cohorts is necessary to validate the observed metabolite changes following Arabic gum intake and their diagnostic value for chronic kidney disease.
Institute	Sharjah Institute for Medical Research
Department	Sharjah Institute for Medical Research
Laboratory	Biomarker Discovery Group
Last Name	Facility
First Name	Core
Address	M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah, Sharjah, UAE, Sharjah, 000, United Arab Emirates
Email	tims-tof@sharjah.ac.ae
Phone	+971 6 5057656
Submit Date	2023-04-09
Raw Data Available	Yes
Raw Data File Type(s)	d
Analysis Type Detail	LC-MS
Release Date	2023-10-10
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002665
Treatment Summary:	For intervention group, Arabic gum in the form of powder twice daily was given, at the dose patients are taking usually over the counter (40 grams of GA in the form of instantly soluble granules to be dissolved in a glass of water or juice and drink it daily for the assigned study period. While for the control group, a placebo was given in the same shape and taste and same frequency. Participants in both groups underwent a 24-hour urine collection for creatinine, protein, and volume at baseline and every three months. eGFR was calculated using the CKD-epi equation [add ref], and lab tests, including serum creatinine, electrolytes, uric acid, serum albumin, phosphate, calcium, PTH, Complete Blood Count (CBC), fasting lipid profile, and urinalysis, were performed at baseline and at 3-month intervals for a year. The objectives of the study were to assess the impact of the intervention on various parameters, including a reduction in the eGFR and the rate of the decline, a decrease in proteinuria, changes in uric acid, electrolytes, calcium, phosphate, vitamin D, and PTH levels, effects on edema, body weight, blood pressure, and anemia parameters.

Treatment ID:

TR002665

Treatment Summary:

For intervention group, Arabic gum in the form of powder twice daily was given, at the dose patients are taking usually over the counter (40 grams of GA in the form of instantly soluble granules to be dissolved in a glass of water or juice and drink it daily for the assigned study period. While for the control group, a placebo was given in the same shape and taste and same frequency. Participants in both groups underwent a 24-hour urine collection for creatinine, protein, and volume at baseline and every three months. eGFR was calculated using the CKD-epi equation [add ref], and lab tests, including serum creatinine, electrolytes, uric acid, serum albumin, phosphate, calcium, PTH, Complete Blood Count (CBC), fasting lipid profile, and urinalysis, were performed at baseline and at 3-month intervals for a year. The objectives of the study were to assess the impact of the intervention on various parameters, including a reduction in the eGFR and the rate of the decline, a decrease in proteinuria, changes in uric acid, electrolytes, calcium, phosphate, vitamin D, and PTH levels, effects on edema, body weight, blood pressure, and anemia parameters.